Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders.
Fiche publication
Date publication
octobre 2020
Journal
European journal of neurology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Louapre C, Maillart E, Papeix C, Zeidan S, Biotti D, Lepine Z, Wahab A, Zedet M, Labauge P, Tilikete C, Pique J, Tourbah A, Mathey G, Dimitri Boulos D, Branger P, Kremer LD, Marignier R, Collongues N, De Seze J
Lien Pubmed
Résumé
Outcomes of coronavirus disease 2019 (COVID-19) in patients with neuromyelitis optica spectrum disorders (NMOSD) or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), often treated with immunosuppressive therapies, are still unknown.
Mots clés
COVID-19, MOGAD, NMOSD, immunosuppressant
Référence
Eur J Neurol. 2020 Oct 26;: